Passaro et al. investigated the inference between baseline clinical factors and 90-day mortality among 321 patients affected by advanced NSCLC with high PD-L1 expression and treated with first-line pembrolizumab [23]. Here, CD274 is linked to non-small cell lung carcinoma.